logo
  

Quaker Chemical Q3 Profit Rises - Quick Facts

Quaker Chemical Corp. (KWR) reported that its third-quarter net income attributable to company increased to $15.70 million from $12.55 million, last year. Earnings per share were $1.18 compared to $0.95 for the third quarter of 2013. Non-GAAP earnings per share was $1.19 for the third quarter of 2014.

On average, five analysts polled by Thomson Reuters expected the company to report profit per share of $1.03 for the quarter. Analysts' estimates typically exclude special items.

Adjusted EBITDA increased 16% to $26.5 million for the third quarter of 2014 compared to $22.8 million for the third quarter of 2013.

Net sales increased to $198.9 million from $184.1 million, prior year , primarily due to higher product volumes. Included in the company's net sales growth for the third quarter of 2014 was 1.7% of additional sales from its acquisition of ECLI Products, LLC. Analysts expected revenue of $191.20 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT